Edition:
United States

Novocure Ltd (NVCR.OQ)

NVCR.OQ on NASDAQ Stock Exchange Global Select Market

36.85USD
14 Aug 2018
Change (% chg)

-- (--)
Prev Close
$36.85
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
200,485
52-wk High
$38.65
52-wk Low
$16.10

Chart for

About

NovoCure Limited is a commercial-stage oncology company. The Company is engaged in developing a cancer treatment centered on a therapy called TTFields, the use of electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Its TTFields delivery system is used for the treatment of glioblastoma (GBM)... (more)

Overall

Beta: --
Market Cap(Mil.): $3,339.85
Shares Outstanding(Mil.): 92.90
Dividend: --
Yield (%): --

Financials

  NVCR.OQ Industry Sector
P/E (TTM): -- 169.61 31.56
EPS (TTM): -1.04 -- --
ROI: -38.43 1.42 12.88
ROE: -81.42 0.52 15.04

BRIEF-Novocure Reports Qtrly Loss Per Share $0.23

* NOVOCURE REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES COMPANY UPDATE

Apr 26 2018

BRIEF-Novocure Says Executive Chairman William Doyle's FY 2017 Total Compensation Was $23.8 Mln

* NOVOCURE LTD SAYS EXECUTIVE CHAIRMAN WILLIAM DOYLE'S FY 2017 TOTAL COMPENSATION WAS $23.8 MILLION - SEC FILING Source : https://bit.ly/2HiWTxC Further company coverage: (Reuters.Briefs@thomsonreuters.com)

Apr 20 2018

BRIEF-Novocure Reports Positive Top-Line Results From Stellar Phase 2 Pilot Trial In Mesothelioma

* NOVOCURE REPORTS POSITIVE TOP-LINE RESULTS FROM STELLAR PHASE 2 PILOT TRIAL IN MESOTHELIOMA

Apr 17 2018

BRIEF-NCCN Guidelines Recommend Novocure's Optune In Combination With Temozolomide

* NCCN GUIDELINES RECOMMEND OPTUNE IN COMBINATION WITH TEMOZOLOMIDE AS A CATEGORY 1 TREATMENT FOR NEWLY DIAGNOSED GLIOBLASTOMA

Mar 20 2018

BRIEF-Novocure Ltd Reports Qtrly Net Loss Per Ordinary Share Of $0.12

* Q4 EARNINGS PER SHARE VIEW $-0.11, REVENUE VIEW $53.5 MILLION -- THOMSON REUTERS I/B/E/S Source text for Eikon: Further company coverage:

Feb 22 2018

Earnings vs. Estimates